iCAD jumps on 3-year Xoft data

|By:, SA News Editor

iCAD (ICAD +2.3%) shares jump after the company presents positive 3-year data for non-melanoma skin cancer treatment efficacy of its Xoft System at the American Society of Radiation Oncology's annual meeting.

The study showed "good cosmesis, low toxicity levels and no recurrences" across a 187 patient cohort.